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Abstract
Background
We aimed to directly compare results from multi-parametric prostate MRI (mpMRI) and a
biopsy-based 17-gene RT-PCR assay providing a Genomic Prostate Score (GPS) among
individuals who were candidates for active surveillance with low and intermediate risk pros-
tate cancer (PCa).
Patients and methods
We evaluated the association between GPS results (scale 0–100) and endorectal mpMRI
findings in men with clinically localized PCa. MR studies were reviewed to a five-tier scale of
increasing suspicion of malignancy. Mean apparent diffusion coefficient (ADC) was calcu-
lated from a single dominant lesion. Mean rank of the GPS (0–100) among MRI strata was
compared with the Kruskal-Wallis test and Dunn’s multiple comparison test. Spearman’s
correlation was performed to examine the association between mean ADC and scaled
GPS.
Results
Of 186 patients who received GPS testing, 100 were identified who received mpMRI. Mean
GPS results differed between mpMRI categories (p = 0.001); however a broad range was
observed in all mpMRI categories. Among men with biopsy Gleason pattern 3+3, mean
GPS results were not significantly different among MRI groups (p = 0.179), but GPS differ-
ences were seen among MRI categories for patients with pattern 3+4 (p = 0.010). Mean
ADC was weakly associated with GPS (σ = -0.151). Stromal response (p = 0.015) and
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cellular organization (p = 0.045) gene group scores differed significantly by MRI findings, but
no differences were seen among androgen signaling or proliferation genes.
Conclusions
Although a statistically significant association was observed between GPS results and MRI
scores, a wide range of GPS values were observed across imaging categories suggesting
that mpMRI and genomic profiling may offer non- overlapping clinical insights.
Introduction
A majority of men diagnosed with prostate cancer (PCa) have what appears to be low and
intermediate-risk disease at presentation on the basis of clinical and pathological factors[1].
Yet the performance of even best clinical prediction instruments will mischaracterize a propor-
tion of men who harbor occult, higher grade or stage disease[2]. The ability to offer improved
risk stratification among such men is therefore important as such efforts may better shape the
trajectory of initial management, a decision choice increasingly defined by active surveillance
(AS) versus immediate treatment[3]. To this end, both tissue-based gene expression assays and
multi-parametric prostate magnetic resonance imaging (mpMRI) have received considerable
attention for the potential to add predictive value beyond conventional clinical models to
determine the presence of high grade or non-organ confined disease and are gaining utiliza-
tion in early disease management[4–7].
Biopsy based assays reflecting the quantitative expression of genes associated with tumor
aggressiveness have demonstrated predictive value for adverse pathology at radical prostatec-
tomy (RP), as well as downstream oncologic endpoints including biochemical recurrence
(BCR) and metastatic progression[8]. In validation studies, these tools have added predictive
performance that exceeds conventional clinical and pathological variables[5]. Similarly, high
resolution MRI examining multiple imaging parameters appears to offer anatomic and biolog-
ical insights into tumor stage and grade that offer higher degrees of accuracy with regard to
clinical staging, tumor localization, and the likelihood of adverse downstream events[9, 10].
It is unclear, however, whether these modalities offer congruent or independent biologic
information. To date, no published studies exist that compare the directionality of these tests
in the same subjects. Specifically, it is unknown whether men with adverse findings on MRI
will derive further benefit from tissue-based assays; or conversely, whether MRI will add
meaningful information to those who have already had tissue based testing. In this context, we
sought to evaluate the association between mpMRI findings and a 17- gene GPS among men
with clinically favorable PCa following initial diagnosis. We hypothesized that a strong correla-
tion would exist between MRI findings and GPS results.
Patients and methods
Patient selection
Under the University of California San Francisco (UCSF) institutional review board approval,
we retrospectively identified all consenting patients with low or intermediate-risk PCa who
underwent a 3T endorectal coil mpMRI and a biopsy-based RT-PCR assay (Oncotype DX1
Prostate Assay) providing a Genomic Prostate Score (GPS) as a measure of tumor aggres-
siveness within a maximum of two years between studies. Patient records were de-identified
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and analyzed anonymously. Among patients with initial biopsy at our institution diagnostic
biopsies were performed using extended sextant systematic sampling techniques including a
minimum of 12 cores; those performed at referring centers were reviewed by genitourinary
pathologists to establish the Gleason score (GS) and volume of disease. Disease risk was
defined using the validated Cancer of the Prostate Risk Assessment score (UCSF-CAPRA)
[11].
mpMRI tests were obtained at the discretion of the providers as a local staging tool for men
with early stage disease who were considering or enrolled in AS to establish disease stability.
MR sequences included T2, high B-value diffusion-weighted imaging (DWI), MR spectro-
scopic imaging (MRSI) and dynamic contrast enhancement (DCE)[12]. Scans were acquired
on a 3-Tesla scanner (GE Healthcare, Waukesha, WI) using the body coil for excitation and an
endorectal coil (E-Coil, Medrad, Pittsburgh, PA) filled with perfluorocarbon and a phased-
array coil for reception. Images were post-processed to compensate for the reception profile of
the endorectal coil. All MRI studies were re-reviewed by a genitourinary radiologist with 10
years of experience blinded to the biopsy and GPS results and graded on a 1–5 scale of increas-
ing suspicion of malignancy, a modification of the PI-RADS version 1 system (Table 1). The
mean apparent diffusion coefficient (ADC) was calculated from a single dominant lesion[13].
The combination of MR imaging and genomic profiling was routinely recommended for men
Table 1. Multi-parametric prostate MRI scoring rubric.
T2 –Peripheral Zone
1 Homogeneous high SI
2 Streaky, triangular, geographic areas of low SI
3 Not 1/2 not 3/4
4 Discrete nodule of low SI
5 Same as 4 + evidence of ECE and/or > 1.5 cm of capsular contact
T2 –Transitional Zone
1 Heterogeneous SI, "organized chaos"
2 Foci of low SI, well marginated /encapsulated
3 Not 1/2 not 3/4
4 Foci of homogeneous low SI, ill defined
5 Same as 4 + evidence of ECE and/or > 1.5 cm of capsular contact
Diffusion Weighted Imaging (DWI)
High B value DWI ADC ADC Value
1 Iso SI Iso SI N/A
2 High SI Iso SI N/A
3 Iso SI Low SI N/A
4 High SI Low SI > 850
5 High SI Low SI < 850
Magnetic Resonance Spectroscopy Imaging (MRSI)
1 Citrate peak 2 x > choline peak
2 Citrate peak 1–2 x > choline peak
3 Citrate peak = choline peak
4 Choline peak 1–2 x > citrate peak
5 Choline peak 2 x > citrate peak
Dynamic Contrast Enhancement (DCE)
+ Asymmetric early enhancement with quick washout or plateau
- Other patterns of enhancement
https://doi.org/10.1371/journal.pone.0185535.t001
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with low and intermediate clinical risk disease prior to enrollment in AS as a means of refined
risk assessment.
The OncotypeDX Prostate Cancer assay (Genomic Health, Inc., Redwood City, CA) was
performed using RNA extracted from fixed paraffin-embedded diagnostic prostate needle
biopsies. This biopsy-based RT-PCR assay generates a Genomic Prostate Score (GPS–scaled
0–100) as a biologic measure of tumor aggressiveness, and has been clinical validated as an
independent predictor of favorable surgical pathology (surgical GS <4+3 and organ-confined
disease) [5] [14]. The GPS represents a weighted calculation of a 17-gene expression signature
including 12 genes highly associated with prostate cancer recurrence and metastases and five
reference genes to control for RNA quality and quantity[5] [15]. The four constituent gene
groups represented in the GPS include androgen signaling (AZGP1, KLK2, SRD5A2,
RAM13C), stromal response (BGN, COL1A1, SFRP4), cellular organization (FLNC, GSN,
TPM2, GSTM2) and proliferation (TPX2).
Statistical analysis
Our primary objective was to evaluate the association between mpMRI findings and GPS
results among an observational cohort of men with clinically localized prostate cancer; we
compared the mean rank of the scaled GPS (0–100) across MRI results characterized as nega-
tive (score 1–2); indeterminate (3); or positive/suspicious (4–5) using the Kruskal-Wallis test.
To examine differences among groups, we further performed a post hoc pairwise analysis
using Dunn’s multiple comparison test, a method that retains the dependent ranking produced
by the Kruskal-Wallis test statistic and incorporates the pooled variance estimate and also pre-
serves the family-wise error rate by using adjusted significance level defined as α/(k(k-1)),
where k is the number of comparisons[16]. To examine particular associations among individ-
ual gene groups with MR findings we repeated the Kruskal-Wallis analyses within expression
Table 2. Baseline characteristics of 100 patients receiving multi-parametric prostate MRI and GPS
testing.
Patient Characteristics Value Statistic
Age (Years), Median (IQR) 62.5 (55.0–68.0)
PSA (ng/ml), Median (IQR) 5.6 (4.3–8.3)
Prostate volume (cm3), Median (IQR) 38.0 (28.0–47.0)
PSA density, Median (IQR) 0.138 (0.098–0.189)
Race/ethnicity, N (%)* Asian/Pacific Islander 2 (2.2)
White 80 (86.0)
Other 11 (11.8)
Clinical T-stage, N (%) T1c 75 (75.0)
T2 25 (25.0)
# Cores taken, Median (IQR) 16.0 (13.0–19.0)
# Cores positive, Median (IQR) 3.0 (1.0–4.0)
% Cores positive, Median (IQR) 17.0 (8.0–25.0)
% Single core positive, Median (IQR) 28.0 (15.0–44.0)
CAPRA, N (%)* Low (0–2) 66 (79.5)
Intermediate (3–5) 16 (19.3)
High (6–10) 1 (1.2)
Abbreviations: IQR = interquartile range; PSA = prostate-specific antigen; CAPRA = Cancer of the Prostate
Risk Assessment
*Due to missing data, totals do not sum to 100 patients
https://doi.org/10.1371/journal.pone.0185535.t002
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scores for all gene groups. As diffusion weighted imaging (DWI) been proposed as a quantita-
tive measurement associated with tumor aggressiveness, we further sought to examine the
association between mean apparent diffusion coefficient (ADC) and GPS using Spearman’s
correlation[17]. Analysis was performed among all pooled 100 patients, as well as stratified by
CAPRA risk category and biopsy GS 3+3 or 3+4. Statistical analyses were performed using
SAS software version 9.3 (SAS Institute, Cary, North Carolina, USA).
Results
Among 186 consented men who have undergone GPS testing at our institution, we identified
100 with mpMRI within a two year window of genomic testing. Compared with men undergo-
ing combined MRI and GPS testing those undergoing GPS testing alone were similarly
matched with regard to baseline demographic and disease characteristics. Among patients
receiving both MRI and GPS median age was 62.5 years and median PSA was 5.6 ng/mL (IQR
4.3–8.3). Biopsies included a median of 16 cores (interquartile range, IQR 13–19), and a
median of three cores were positive for cancer (IQR 1–4). 53 men had biopsy GS3+3 and 47
GS 3+4. The majority of patients (n = 63) sought initial management with AS while 41 ulti-
mately underwent treatment with radical prostatectomy. The complete clinical and pathologic
features are presented in Table 2.
MRI findings were negative in 13 patients, indeterminate in 26, and positive in 61. The
median GPS was 16 (IQR 13–21) for men with negative, 23 (IQR 14–27) for indeterminate
and 28 for positive (IQR 21–34) MRI studies, Fig 1. There was a significant difference in the
mean rank of the GPS results among the 3 MRI categories (p = 0.001) for the entire group of
100 patients, with mean GPS increasing with increasing MRI category. Nonetheless there was
a wide distribution of GPS values within each MRI category. When patients were stratified by
biopsy GS, no significant association (p = 0.18) was observed between GPS and MRI in
patients with GS 3+3 (Fig 2A), however there was a significant association among men with
GS 3+4 tumors (p = 0.010 –Fig 2B). Post-hoc pairwise comparisons showed significant differ-
ence in mean rank of GPS between negative and positive MRI categories (p<0.001), however
no statistically significant difference was observed between negative and indeterminate or pos-
itive and indeterminate results. Among men with high suspicion MRI lesions we evaluated the
association between scaled GPS results and meanADC values. A weak trend towards higher
GPS results was observed with lower meanADC values, (Rho = -0.151), (Fig 3).
To determine whether further associations may exist within individual gene pathways mea-
sured by GPS and MRI findings, we examined the association of gene group expression levels
with MRI findings. Stromal response and cellular organization gene expression scores showed
a modest but statistically significant association with MRI category (p = 0.015 and p = 0.045,
respectively), however no significant trends were observed in androgen response or prolifera-
tion (p = 0.101 and 0.074, respectively). meanADC also exhibited weak association with indi-
vidual gene groupings (stromal response: Rho = -0.221; cellular organization Rho = -0.01;
androgen signaling Rho = 0.106; and proliferation Rho = 0.01). Within each gene pathway,
considerable variation in expression levels was observed among all MRI groups, particularly
among the 61 patients with category 4 and 5 lesions (Fig 4A–4D).
Discussion
The limitations of conventional clinical variables to reliably characterize the extent of disease
among men with newly diagnosed PCa have been met with a growing arsenal of tools aimed to
improve risk estimation in early stage disease. Genomic signatures have been validated to pre-
dict the occurrence of higher grade or stage elements among clinically favorable risk patients,
Association of MRI and genomic profiling in men with prostate cancer
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while high resolution mpMRI as both an anatomic and biologically informative modality has
received extensive study for the ability to detect significant cancer[4, 5, 18]. Comparative anal-
yses of such advanced risk stratification tools, however, are lacking and it remains unclear
Fig 1. Distribution of GPS scores by MRI findings among all 100 patients.
https://doi.org/10.1371/journal.pone.0185535.g001
Fig 2. A. Distribution of GPS results by MRI findings among men with biopsy Gleason grade 3+3 and B. Among patients with
Gleason grade 3+4.
https://doi.org/10.1371/journal.pone.0185535.g002
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whether individuals who have received MR imaging will derive further benefit from genomic
testing, or conversely, if imaging may be of benefit among men following tissue-based assays.
In this study, we examined the association between MRI findings and the GPS signature in
a cohort of 100 men with clinically favorable risk PCa undergoing evaluation with both modal-
ities. Although a trend towards higher GPS results existed among higher MR-suspicion lesions,
we observed considerable variation across all mpMRI findings, suggesting biologic heteroge-
neity within each of the MRI categories. Among men without MR-evident tumors, GPS results
tended to be lower and more narrowly distributed, however this represented a minority of
patients in the study (13%). For men with indeterminate or positive MR studies, GPS results
ranged significantly, a relationship that persisted after stratification by GS or clinical risk
group. Though not directly correlated with patient outcome, these findings suggest that further
clinical refinement may be possible among patients beyond MRI findings alone.
The GPS assay is derived from a set of highly predictive genes in a fashion independent of
Gleason pattern, and has been validated by independent studies as a predictor of pathological
upgrading and/or upstaging among men with favorable risk disease [5] [14]. It has also been
shown to predict distant oncological outcomes, including biochemical recurrence and meta-
static progression[5, 14]. We speculated that imaging findings would recapitulate tumor gene
expression levels: higher suspicion MRI lesions would be associated with higher GPS scores,
higher expression levels of stromal response and proliferation genes would be associated with
MR-evident disease, and that areas of restricted diffusion would be associated with higher GPS
findings. We observed that GPS results were significantly different among patients with
Fig 3. Relationship between meanADC value (mm2/s) of the dominant MRI lesion and GPS result.
https://doi.org/10.1371/journal.pone.0185535.g003
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negative, indeterminate, or positive MRI scans, and among men with biopsy pattern 3+4,
though no significant differences were seen among MRI groups for men with biopsy pattern 3
+3. Moreover, stromal response and cellular organization gene expression scores were associ-
ated with MR findings, though no associations were seen among androgen signaling or prolif-
eration groups. As prior clinical validation studies have demonstrated significant associations
of the four primary gene groupings with clinical outcome, including recurrence, these finding
may indicate a novel radiomic basis for stromal response and cellular organization genes and
MR pattern. Taken together these findings suggest that a degree of agreement in signal direc-
tion exists between MRI and the GPS assay, however the information provided by these two
modalities appears to be largely non-overlapping.
The prognostic significance of a visible lesion on mpMRI has been evaluated on several
PCa endpoints including the detection of higher grade (Gleason3+4) disease on biopsy[19],
progression during AS, high grade/stage pathology at prostatectomy[20], and biochemical
recurrence[21]. For men with newly diagnosed PCa, the presence of MRI-discernable lesions
has been suggested as an adverse prognostic characteristic particularly for men initiating man-
agement with AS, where retrospective studies have suggested an increased risk for disease
Fig 4. A-D. Distribution of individual gene group expression levels among mpMRI categories.
https://doi.org/10.1371/journal.pone.0185535.g004
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reclassification due to changes in tumor volume estimates[22]. As MRI studies incorporate
multiple sequences believed to reflect anatomic, tumor vascularity, and cellularity it is not
known whether higher rates of upgrading reflect improved sampling associated with larger
tumors in some men or the occurrence of genuine biological progression.
Though MRI has exhibited the capacity to identify higher Gleason pattern PCa, the genetic
mechanisms underlying characteristic MRI findings remain to be fully elucidated. In this
study mean, ADC values exhibited weak, negative correlation with overall GPS or constituent
gene groups. These findings are notable given prior studies addressing the association of
apparent diffusion coefficient (ADC) analysis and prostate cancer aggressiveness[17]. The
directionality of the relationship is consistent with the implication of restricted diffusion with
tumor aggressiveness, however the strength of the association appears to imply that meanADC
analysis does not closely parallel a panel of genes highly associated with PCa aggressiveness.
We included biopsy samples obtained using systematic extended sextant sampling and not
direct MR-ultrasound fusion acquisition, reflecting the era of collection at our institution. As a
result, we were not able to compare gene expression profiles on a per-lesion basis. In addition,
because of a growing appreciation for improved diagnostic yield associated with MR-ultra-
sound fusion, it is conceivable that some degree of undersampling may be present relative to a
targeted method[18] [23]. As the GPS assay has been previously shown to predict prostate can-
cer aggressiveness in the face of biopsy under-sampling and heterogeneity in Gleason grade,
our approach may hold validity in assessing the broader tumor profile of the gland, though fur-
ther study is warranted using image-guidance or whole-mount correlation[5]. In this regard,
important insights appear to be offered by intriguiging preliminary directed radiomic study
matching gene expression to gene expression features. For example, in an analysis of 17
mpMRI-directed diagnostic biopsies, associations were observed between radiographic abnor-
malities and aberrant gene expression, highlighting a measurable molecular basis for charac-
teristic MR findings [24].
An acknowledged limitation of this study is that our comparison is restricted to the two
modalities themselves without direct evaluation of clinical outcomes. This finding reflects the
favorable risk nature of the study cohort and the routine use of AS for initial management in
appropriate candidates. As a result, only a small proportion received immediate definitive
treatment with prostatectomy, which limited our ability to offer a pathological comparison.
Additionally, although patients receiving genomic testing with or without MRI were evenly
matched, we cannot conclude with certainty that the decision to pursue both MRI and GPS
testing in these patients occurred at random. While individuals may opt for multiple modali-
ties of advanced testing due to preference, it is possible that such patients possessed unrecog-
nized clinical complexity which warranted additional evaluation. In addition, all MR images
were reviewed by a single radiologist, which may limit reproducibility. We utilized a two-year
interval between MRI and GPS testing as inclusion criteria under the assumption of disease
stability during this time based on modeling and observational studies, however we cannot
exclude that changes in tumor biology may have occurred during this time period[25, 26].
Lastly, the study design did not examine GPS results from biopsies of selected MRI abnormali-
tites. Given the growing utilization of MRI-ultrasound fusion platforms affording directed
sampling of MR-apparent lesions, this limitations prevented us from comparing in genomic
profiles based on direct biopsy.
Both tissue based genomic profiling and MRI seek to offer refined clinical staging and risk
stratification at the time of diagnosis, including the risk of adverse pathology at the time of sur-
gery. A host of publications support the use of MRI to predict clinical stage, and presence for
extraprostatic extension or seminal vesicle invasion [27]. Similarly, the GPS assay has been
clinically validated to predict pathologic outcomes among two studies including 732 patients
Association of MRI and genomic profiling in men with prostate cancer
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receiving radical prostatectomy[28]. As patients in this study received imaging and genomic
profiling in the clinical context of establishing eligibility for AS, a minority (n = 41) underwent
treatment with prostatectomy at last follow. As a resut, direct comparisons are limited due to
sample size, and selection bias as patients often receive treatment in the context of biopsy
upgrade or concern for progression. To optimally detect significant differences in gene expres-
sion across five strata of MRI findings corresponding to all PI-RADS classifications, we esti-
mate that over 300 patients would be required. Further, appropriately powered studies are
required to assess the relative clinical utility of imaging and genomic profiling in initial risk
stratification.
Few other studies have directly compared associations among a new generation of PCa risk
prediction tools. Recently, Renard-Penna et al. examined 106 patients treated with RP in
whom pre-operative mpMRI findings were compared with genomic testing of tumor tissue
with a 31-gene cell progression assay as a measure of aggressiveness, noting associations
among tumor size and diffusion abnormalities with adverse cell-cycle progression (CCP)
scores[29]. Interestingly, the authors utilized CCP as a benchmark for assessing the perfor-
mance of preoperative imaging, however, a valuable opportunity remains to compare these
modalities, particularly in the pre-treatment setting. As the inventory for such risk refinement
aids expands in size and complexity, it is likely that such direct comparisons will be of increas-
ing clinical impact and potentially serve to more efficiently direct resources. Our findings
suggest that mpMRI and the 17-gene GPS assay offer predictive information that may be dis-
tinctive in many circumstances reflecting intrinsic differences between these tools. Prostate
MR scoring systems, including the PI-RADS framework, have been developed and calibrated
to detect clinically significant cancer apprised largely on the basis of Gleason score, a powerful
though altogether incomplete predictor of disease outcome[30]. In contrast, the genes selected
for the GPS assay and their relative weights within the generated score were validated to pre-
dict adverse pathologic and oncological events independently of pathological assessment. As a
result, we anticipated that heterogeneity in gene expression levels would exist within MRI
groups, a finding which underscores the clinical variability within MRI groups.
The intersection of multiple PCa risk refinement tools in early stage PCa is a presently
unexplored avenue of investigation with implications for disease management. Our findings,
reflecting one commercial assay, demonstrate stratification among MRI findings, yet are,
alone, inadequate to dictate definitive clinical sequencing of these tests. Additional compara-
tive studies of imaging and serum detection-oriented biomarkers may also prove fruitful in
clarifying optimal diagnostic pathways. Additionally, larger study populations assessing down-
stream PCa outcomes will be required to assess the optimal sequencing of such emerging
modalities.
Conclusion
We compared mpMRI and tissue based gene expression testing among low and intermediate
clinical risk patients. Prostate MRI and genomic testing with the GPS assay exhibited weak
correlation, suggesting that the two modalities represent independent predictors and may be
complementary in guiding patient management.
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